

CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis

Jason N. Dungu, MBBS, BSc,*†, Oswaldo Valencia, MSc, MD,†, Jennifer H. Pinney, BM, BS,*
Simon D. J. Gibbs, MBBS,* Dorota Rowczenio, MSc,* Janet A. Gilbertson, CSci,*
Helen J. Lachmann, MD,* Ashutosh Wechalekar, MD,* Julian D. Gillmore, MD, PhD,*
Carol J. Whelan, MD,* Philip N. Hawkins, PhD,* Lisa J. Anderson, MD†

London, United Kingdom

OBJECTIVES This study was devised to describe the different cardiac magnetic resonance (CMR) appearances in light chain amyloid (AL) and transthyretin-related amyloidosis (ATTR).

BACKGROUND CMR is increasingly used to investigate patients with suspected amyloidosis. Global subendocardial late gadolinium enhancement (LGE) has been reported as typical of AL amyloidosis, whereas different patterns have been noted in ATTR amyloidosis.

METHODS We performed de novo analyses on original DICOM magnetic resonance imaging in 46 patients with cardiac AL amyloidosis and 51 patients with ATTR type who had been referred to a specialist amyloidosis center between 2007 and 2012 after CMR. Histological examination was performed in all cases, with immunohistochemistry, to confirm systemic amyloidosis.

RESULTS Patients' median age was 68 ± 10 years, and 74% were male. Left ventricular mass was markedly increased in ATTR amyloidosis (228 g [202 to 267 g]) compared with AL type (167 g [137 to 191 g]) ($p < 0.001$). LGE was detected in all but 1 cardiac amyloidosis patient (AL type) and was substantially more extensive in ATTR compared with AL amyloidosis. Ninety percent of ATTR patients demonstrated transmural LGE compared with 37% of AL patients ($p < 0.001$). Right ventricular LGE was apparent in all ATTR patients but in only 33 AL patients (72%) ($p < 0.001$). Despite these findings, survival was significantly better in cardiac ATTR amyloidosis compared with AL type. We derived an LGE scoring system (Query Amyloid Late Enhancement) that independently differentiated ATTR from AL amyloidosis and, when incorporated into a logistic regression model with age and wall thickness, detected ATTR type with 87% sensitivity and 96% specificity.

CONCLUSIONS Transmural patterns of LGE distinguished ATTR from AL cardiac amyloidosis with high accuracy in this real-world analysis of CMR. Precise diagnosis of cardiac amyloidosis is crucial given the role of chemotherapy in AL type and with novel therapies for ATTR type currently in development. (J Am Coll Cardiol Img 2014;7:133–42) © 2014 by the American College of Cardiology Foundation

From the *National Amyloidosis Centre, UCL Medical School, Royal Free Campus, London, United Kingdom; and †Cardiovascular Sciences, St. George's University of London, London, United Kingdom. Dr. Dungu is supported by a British Heart Foundation Clinical Research Training Fellowship grant (FS/09/063/28026). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received July 25, 2013; accepted August 23, 2013.

Systemic amyloidosis is a condition characterized by extracellular deposition of pathologic insoluble fibrillar proteins (1). Cardiac light chain amyloid (AL) amyloidosis, in which amyloid fibrils are derived from monoclonal immunoglobulin light chains, is associated with poor prognosis, with a median survival from diagnosis of <12 months (2,3). The prognosis of transthyretin-related amyloidosis (ATTR) is typically 3 to 5 years (4). Transthyretin (TTR) is a plasma protein,

See page 166

predominantly synthesized in the liver, which acts as a transporter for thyroxine and retinol-binding protein (5). Senile systemic amyloidosis due to nonmutant (wild-type) TTR is a sporadic disease among older people presenting as isolated cardiomyopathy. Hereditary ATTR amyloidosis is an autosomal dominant disease associated with >100 transthyretin gene mutations (6). Cardiac involvement is now known to occur in association with most hereditary ATTR variants.

There has been a marked increase (143%) in new cases of ATTR amyloidosis referred to our center in the past 5 years (4). The increased detection of ATTR amyloidosis correlates with increased availability of cardiac magnetic resonance (CMR) for investigation of cardiomyopathy. Gadolinium-enhanced CMR visualizes expansion of the interstitial space and may be used to demonstrate the accumulation of abundant amyloid in this site (7). An early CMR study in cardiac amyloidosis described altered gadolinium kinetics, difficulty nulling the myocardium, and a global subendocardial

pattern of late gadolinium enhancement (LGE) (8). However, the precise pattern of LGE has been reported to be more variable in recent studies (9,10). Our impression has been that LGE is often diffuse in ATTR amyloidosis (4), but very few ATTR patients have been included in CMR studies, and there are no reports of differences in LGE patterns according to amyloid fibril protein type. We report here the standard CMR measurements and LGE patterns in the largest cohort of cardiac ATTR amyloidosis patients characterized by using CMR at the time of writing.

METHODS

Patients were identified between January 2007 and June 2012 at the UK National Amyloidosis Centre,

a specialist referral center for the analysis of systemic amyloidosis. All patients had a CMR scan for the investigation of suspected amyloidosis. Histological examination was performed in all cases, with immunohistochemistry, to confirm or rule out systemic amyloidosis. Cardiac amyloidosis was confirmed according to results of endomyocardial biopsy, with Congo red staining and immunohistochemistry to determine the amyloid type. In the absence of cardiac histology analysis, patients were diagnosed with cardiac amyloidosis if there were extracardiac biopsy results confirming systemic amyloidosis, immunohistochemistry to determine the amyloid fibril type and echocardiographic criteria for cardiac amyloidosis (11). Transthyretin gene sequencing to differentiate wild-type and mutant TTR was performed in all cases of ATTR amyloidosis.

We obtained the raw CMR DICOM data for all patients. De novo analysis was performed with dedicated software (CMRtools 2012, Cardiovascular Imaging Solutions, London, United Kingdom) and reported according to international guidelines (12). Left ventricular (LV) volumes and mass were indexed to body surface area. Patterns of LGE were described in the left ventricle at 3 levels (base, mid-ventricle, and apex) and in the right ventricular (RV) free wall and atrium (present or absent). The LGE pattern was described as transmural if it involved the subendocardium through to the epicardial layer.

Subendocardial LGE was described if there was global subendocardial involvement but no transmural LGE. Nulling was defined as dark, unenhanced areas within the myocardium or skeletal muscle in LGE images. The presence of pericardial and pleural effusion was also recorded.

The study was approved by the ethics committee of the Royal Free Hospital, and patients provided informed written consent.

Statistics. Statistical analysis was performed using SPSS version 17.0 (IBM SPSS Statistics, IBM Corporation, Armonk, New York) or later statistical packages. Parametric data are presented as mean \pm 1 SD. Nonparametric data are presented as median and interquartile range, and categorical data are presented as frequencies and percentages. Comparison of categorical data was performed using the chi-square test. Continuous variables were compared using the unpaired Student *t* test for parametric data and the Wilcoxon signed rank test and Mann-Whitney test for nonparametric data. Nonparametric correlations were performed by using Spearman's rank coefficient. Survival analysis was performed to September 2012 with mortality

ABBREVIATIONS AND ACRONYMS

AL = light chain amyloid

ATTR = transthyretin-related amyloidosis

CI = confidence interval

CMR = cardiac magnetic resonance

DPD = ^{99m}Tc -3,3-diphosphono-1,2-propanodicarboxylic acid

LGE = late gadolinium enhancement

LV = left ventricular

LVEF = left ventricular ejection fraction

NT-proBNP = N-terminal pro-B-type natriuretic peptide

QALE = Query Amyloid Late Enhancement

RV = right ventricular

TTR = transthyretin

data linked to the UK Office of National Statistics. Survival is presented as Kaplan-Meier curves, with the log-rank test used to compare groups. Multivariate regression analyses were made with all independent categorical and continuous variables that appeared significant ($p < 0.05$) and using backward stepwise (likelihood ratio) logistic regression analysis. Intraclass correlation was used to evaluate interobserver measurement reliability, expressed as a single measure calculation.

RESULTS

A total of 115 CMR studies were obtained. We performed complete analysis of 108 studies; 7 scans with insufficient data were not included in the analyses. Studies were received from 46 different centers. Only 1 center (St. George's Hospital in South London) performed >10 of the studies analyzed in this series (24 [22%]). Most studies (84%) were performed at 1.5-T field strength; 17 studies (16%) were performed at 3.0-T field strength.

A final diagnosis of cardiac amyloidosis was made in 100 patients (93%). The cardiac amyloidosis type was AL in 46 patients (46% [83% lambda and 17% kappa type]) and ATTR in 51 patients (51%, including 28 patients with senile systemic amyloidosis secondary to wild-type nonmutant ATTR and 23 patients with hereditary amyloidosis secondary to mutant TTR). Non-AL, non-TTR cardiac amyloidosis was diagnosed in 3 patients (3%; AA amyloidosis (causative protein serum amyloid A [SAA]) in 2 patients and apolipoprotein A1 in 1 patient). Cardiac histology results were available in 50 patients overall (46.3%), but the remaining patients all had extracardiac biopsy confirmation of systemic amyloidosis, and cardiac involvement was defined according to international guidelines (11).

Cardiac amyloidosis was ruled out on the basis of endomyocardial biopsy results in 6 patients after a CMR report with amyloid in the differential diagnosis. The final diagnosis in patients without cardiac amyloidosis was as follows: hypertensive cardiomyopathy in 3 patients, hypertrophic cardiomyopathy in 2 patients, and alcoholic cardiomyopathy in 1 patient. Results of CMR were normal in 2 patients with systemic AL amyloidosis in whom cardiac involvement was ruled out according to conventional echocardiographic criteria. (See [Online Fig. 1](#) for a flowchart of patients included in the study.)

Differentiating cardiac ATTR from cardiac AL amyloidosis. We focused on the differences between cardiac AL and ATTR amyloidosis, the most

common causes of cardiac involvement in systemic amyloidosis.

BASELINE CHARACTERISTICS. Baseline differences between AL and ATTR amyloidosis are presented in [Table 1](#). Patients with cardiac ATTR amyloidosis were older (74 vs. 63 years; $p < 0.001$) compared with cardiac AL amyloidosis patients and predominantly male (88% vs. 59%; $p = 0.009$). There was no significant difference in New York Heart Association functional class at presentation or N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration according to amyloid fibril type in this cohort.

SURVIVAL. Median survival from the date of diagnosis in patients with cardiac ATTR amyloidosis was better (45 months) compared with cardiac AL amyloidosis (18 months) ($p = 0.007$) ([Fig. 1](#)).

CMR: CARDIAC DIMENSIONS AND FUNCTION. LV volumes and left ventricular ejection fraction (LVEF) were within the normal range, when indexed for body surface area, in cardiac AL and ATTR amyloidosis ([Table 2](#)). LV end-diastolic and end-systolic volumes were significantly lower in AL compared with ATTR amyloidosis, but LV stroke volume was similar in both amyloid types (71 ± 19 ml vs. 72 ± 20 ml; $p = 0.997$). Thus, LVEF was significantly lower in cardiac ATTR compared with AL amyloidosis (56% vs. 64%; $p = 0.002$), albeit with absolute and indexed values within the normal range for both amyloidosis

Table 1. Baseline Differences Between Cardiac AL and ATTR Amyloidosis Patients

	Cardiac AL Amyloidosis (n = 46)	Cardiac ATTR Amyloidosis (n = 51)	p Value
Age, yrs	63 \pm 9	74 \pm 7	<0.001
Male	27 (59)	45 (88)	0.009
Hypertension	6 (13)	10 (20)	0.38
NYHA functional class			
I	10 (22)	7 (14)	0.59
II	23 (50)	28 (55)	
III	13 (28)	15 (29)	
IV	0 (0)	1 (2)	
NT-proBNP, pMol/l	593 (172–1106)	497 (279–777)	0.48
Symptom duration before diagnosis, months	11 (8–23)	11 (6–24)	0.70
Median survival, months	18	45	0.007

Values are mean \pm SD, n (%), or median (interquartile range).
AL = light chain amyloid; ATTR = transthyretin-related amyloidosis; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association.




Figure 1. Survival in Amyloidosis

Kaplan-Meier survival curves for cardiac light chain amyloid (AL) and transthyretin-related (ATTR) amyloidosis (median survival 18 months and 45 months, respectively, from the date of diagnosis [$p = 0.007$]).

subtypes. LV mass index was only mildly increased in cardiac AL amyloidosis but was markedly increased in cardiac ATTR compared with AL amyloidosis. Interventricular septum and RV free wall thickness were increased in both amyloidosis types, with significantly increased wall thickness in cardiac ATTR (left ventricle 18 ± 2 mm; right ventricle 8 ± 2 mm) compared with cardiac AL amyloidosis (left ventricle 14 ± 3 mm; right ventricle 6 ± 2 mm) ($p < 0.001$). Pleural effusions were common despite preserved LVEF (observed in 57% of cardiac AL patients and 41% of ATTR amyloidosis patients [$p = 0.13$]). There was no significant difference in the prevalence of pericardial effusions according to amyloid type (AL 37%; ATTR 33% [$p = 0.71$]).

CMR: LGE. LGE was present in all patients with cardiac ATTR amyloidosis and 45 (98%) of 46 patients with cardiac AL amyloidosis (Table 3). One male patient with cardiac AL amyloidosis according to conventional echocardiographic criteria did not demonstrate any LGE in the context of increased LV thickness (13 mm), increased LV mass index (93 g/m^2), and preserved systolic function (LVEF 75%). RV free wall LGE was detectable in all patients with ATTR amyloidosis but in only 33 patients (72%) with cardiac AL amyloidosis ($p < 0.001$), possibly due to a lesser degree of RV thickening in AL amyloidosis. RV wall thickness was significantly higher in patients with detectable RV LGE (7 ± 2 mm) compared with patients without RV LGE (5 ± 2 mm) ($p < 0.001$). Atrial

LGE was detectable in 47 ATTR patients (92%) and 34 cardiac AL amyloidosis patients (74%) ($p = 0.02$). The previously reported global sub-endocardial pattern of LGE (8) was present in 18 AL patients (39%) and only 6 ATTR patients (12%) ($p = 0.002$). The prevalence of any transmural LGE was significantly higher in patients with cardiac ATTR amyloidosis ($n = 46$ [90%]) than cardiac AL amyloidosis ($n = 17$ [37%]) ($p < 0.001$). A base-apex gradient (more extensive uptake at the base compared with the apex) (Fig. 2) was present in 36 cardiac ATTR patients (71%) and 19 cardiac AL patients (41%) ($p = 0.004$). Global transmural LGE throughout the left ventricle was evident in 11 ATTR patients (22%) but in only 2 patients with cardiac AL amyloidosis (4%) ($p = 0.01$).

Quantification of LGE in cardiac amyloidosis. The extent of LGE in ATTR amyloidosis was strikingly greater than that observed in AL amyloidosis. We devised a new retrospective analysis tool to semi-quantitatively assess the degree of LGE in patients with suspected cardiac amyloidosis (Fig. 3). The Query Amyloid Late Enhancement (QALE) score was performed on LGE images at the base, mid-ventricle, and apex. The maximum LV LGE score at each level is 4 (maximum LV LGE score 12), plus 6 if RV LGE is present. The QALE score range is 0 (no LGE in the left or right ventricle) to 18 (global transmural LV LGE with RV involvement).

A significant, positive correlation was demonstrated between QALE score and interventricular septal thickness (Spearman's $\rho = 0.344$, $p < 0.001$), LV mass index (Spearman's $\rho = 0.348$, $p < 0.001$), LV end-diastolic volume index (Spearman's $\rho = 0.206$, $p = 0.033$), and LV end-systolic volume index (Spearman's $\rho = 0.269$, $p = 0.005$). A negative correlation was demonstrated between QALE score and LVEF (Spearman's $\rho = -0.267$, $p = 0.005$). No significant correlation was observed between QALE score and LV stroke volume index (Spearman's $\rho = 0.011$, $p = 0.910$), NT-proBNP (Spearman's $\rho = 0.068$, $p = 0.487$), or duration of symptoms (Spearman's $\rho = -0.054$, $p = 0.579$).

Multivariate regression analysis was performed by using clinical and CMR variables (age, sex, interventricular septum thickness, LV mass, and QALE score). The QALE score was identified as an independent predictor of amyloid type (odds ratio: 1.9 [95% confidence interval (CI): 1.2 to 3.0]; $p = 0.007$) (Online Table 1). A score model for the detection of ATTR amyloidosis was

developed as a logistic probability unit ($z = \logit [p] = \log e (p/1-p)$; $p = 1/1+e^{-z}$) by using the most significant variables: age and interventricular septum thickness with or without QALE score. A receiver-operating characteristic curve was developed for the scores (Fig. 4). A QALE score ≥ 13 differentiated ATTR from AL type with 82% sensitivity and 76% specificity. The logistic score with QALE included was the most accurate, with 87% sensitivity and 96% specificity to detect ATTR amyloidosis.

REPRODUCIBILITY OF QALE SCORE. All CMR scans were reported by a second blinded observer to determine the interoperator variability of QALE scoring. The second observer reviewed the entire study and recorded the QALE score in the left ventricle (3 levels) and the right ventricle. The intraclass correlation coefficient was 0.66 (95% CI: 0.53 to 0.76), confirming fair agreement between the 2 independent observers. Bland-Altman analysis (13) demonstrated a mean difference of -1.28 (95% CI: for mean difference -0.48 to -2.09) (Fig. 5).

Comparison with CMR reports: all patients. TRUE POSITIVE AND TRUE NEGATIVE CMR REPORTS. The referring hospital CMR report correctly identified cardiac amyloidosis in 88 patients and correctly ruled out cardiac amyloidosis in 2 patients with systemic AL amyloidosis who had no evidence of cardiac involvement according to conventional echocardiographic criteria.

FALSE-POSITIVE CMR REPORTS. Cardiac amyloidosis was ruled out on the basis of endomyocardial biopsy results in 6 patients after CMR reported findings suggestive of amyloid cardiomyopathy. The false-positive cases are summarized in Online Table 2. All 6 patients were male, with Afro-Caribbean ethnicity in 4 cases, and all showed LGE on CMR imaging, but extensive myocardial fibrosis was demonstrated according to histology in each case with negative Congo red staining. The pattern of LGE was variable, but diffuse mid-wall LGE was seen in 2 hypertensive Afro-Caribbean patients (Fig. 6). None of the patients with false-positive reports demonstrated transmural LGE or a base-apex gradient.

FALSE-NEGATIVE CMR REPORTS. Cardiac amyloidosis had not been included in the differential diagnosis for 12 patients in whom cardiac amyloidosis was later confirmed using conventional echocardiographic criteria, including 11 patients with AL type and 1 patient with ATTR type. The conclusions of the reports were as follows: “not suggestive of

Table 2. Comparison of AL and ATTR Amyloidosis (CMR)

	AL Amyloidosis (n = 46)	ATTR (n = 51)	p Value
LVEDV, ml	114 ± 31	131 ± 39	0.023
Men (normalized range 60–95 ml)	64 ± 16	69 ± 20	0.258
Women (normalized range 53–87 ml/m ²)	60 ± 16	62 ± 11	0.789
LVESV, ml	43 ± 20	59 ± 28	0.001
Men* (normalized range 14–36 ml/m ²)	24 ± 10	32 ± 15	0.011
Women† (normalized range 13–31 ml/m ²)	22 ± 13	25 ± 12	0.632
LV SV, ml	71 ± 19	72 ± 20	0.997
Men* (normalized range 40–64 ml/m ²)	41 ± 11	38 ± 10	0.256
Women† (normalized range 36–60 ml/m ²)	37 ± 9	37 ± 4	0.944
LVEF, %	64 ± 12	56 ± 12	0.002
Men* (range 55%–81%)	63 ± 11	55 ± 12	0.008
Women† (range 57%–81%)	66 ± 13	62 ± 14	0.538
LV mass, g	167 (137–191)	228 (202–267)	<0.001
Men* (normalized range 57–90 g/m ²)	93 (82–106)	122 (106–140)	<0.001
Women† (normalized range 48–78 g/m ²)	83 (67–102)	104 (95–116)	0.050
Interventricular septum thickness, mm	14 ± 3	18 ± 2	<0.001
RV free wall thickness, mm	6 ± 2	8 ± 2	<0.001
Left atrium area, cm ²	23 ± 7	26 ± 7	0.04
Right atrium area, cm ²	20 ± 7	25 ± 8	0.001
Pericardial effusion	17 (37)	17 (33)	0.71
Pleural effusion	26 (57)	21 (41)	0.13

Values were indexed for body surface area and are mean ± SD, median (interquartile range), or n (%). *AL = 28 male patients; ATTR = 45 male patients. †AL = 19 female patients; ATTR = 6 female patients.

CMR = cardiac magnetic resonance; LV = left ventricular; LVEDV = left ventricular end-diastolic volume index; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; RV = right ventricular; SV = stroke volume; other abbreviations as in Table 1.

cardiac amyloidosis” in 5 patients; “inconclusive” in 2 patients; “consistent with hypertrophic cardiomyopathy” in 2 patients; “consistent with myocardial infarction” in 2 patients; and “possible Fabry’s disease” in 1 patient. LGE was evident in all cases. Only 1 patient demonstrated the previously reported global subendocardial LGE pattern (8). The other patterns of LV LGE in false-negative CMR scans were transmural in ≥ 1 segment in 6 patients (50%), patchy (n = 4), or mid-wall with apical sparing (n = 1). RV LGE was evident in 8 patients (67%), and a base-apex gradient was evident in 5 patients (42%). Pleural effusions were evident in 6 patients (50%) despite normal LVEF and volumes.

Table 3. Comparison of AL and ATTR Amyloidosis (LGE)

	Cardiac AL Amyloidosis (n = 46)	Cardiac ATTR (n = 51)	p Value
LV LGE	45 (98)	51 (100)	0.47
RV LGE	33 (72)	51 (100)	<0.001
Global subendocardial LGE	18 (39)	6 (12)	0.002
Global transmural LGE	2 (4)	11 (22)	0.01
Any transmural LGE	17 (37)	46 (90)	<0.001
Base-apex gradient	19 (41)	36 (71)	0.004
Atrial LGE	34 (74)	47 (92)	0.02
Suboptimal myocardial nulling	8 (17)	17 (33)	0.07

Values are n (%).

LV = left ventricular; LGE = late gadolinium enhancement; RV = right ventricular; other abbreviations as in Table 1.

Non-AL, non-ATTR cardiac amyloidosis. CMR in 2 patients with cardiac AA amyloidosis (1 male age 70 years, 1 female age 60 years) demonstrated moderate LV thickening (16 and 15 mm, respectively), normal/mildly increased LV mass index (82 and 91 g/m²), low normal LV end-diastolic volume index (58 and 61 ml/m²), very low LV end-systolic volume index (both 10 ml/m²), and high LVEF (82% and 84%). The pattern of LGE was diffuse with transmural involvement and a base-apex gradient in both cases, similar to that seen in ATTR amyloidosis. A 50-year-old female patient with cardiac apolipoprotein A1 (variant L60R) amyloidosis demonstrated mildly increased wall thickness (13 mm), normal LV mass, reduced LV volumes, high LVEF (78%), and subendocardial LGE with transmural involvement of the


lateral wall (more similar to the AL pattern of LGE).

DISCUSSION


Cardiac amyloidosis of all types is associated with LV volumes and LVEF within the normal range at presentation, but LV wall thickness and mass index are increased. In our experience, preserved LVEF by echocardiography is uncommon as the disease progresses and it should be noted that the CMR scans in this series were performed early, often before a formal diagnosis had been made, and not repeated. Cardiac ATTR amyloidosis is associated with significantly higher LV mass index, higher LV volumes, and lower LVEF compared with cardiac AL amyloidosis. Pleural and pericardial effusions were more common in cardiac AL amyloidosis, despite better LVEF and smaller LV volumes, although not statistically significant.

LGE was evident in all but 1 patient with cardiac AL amyloidosis in this series. Two patients with systemic AL amyloidosis and no evidence of cardiac involvement according to conventional echocardiographic criteria had completely normal CMR scans. The pattern of LGE in cardiac ATTR amyloidosis was more extensive, with RV enhancement detected in all cases and a higher prevalence of transmural LV LGE. The absence of detectable RV free wall LGE in more than one-quarter of patients with cardiac AL amyloidosis may distinguish the 2 subtypes; however, the difference in detection of RV LGE may be explained by increased RV wall thickness in ATTR amyloidosis. Suboptimal myocardial nulling was a frequent finding in this series and in itself should raise suspicion of amyloid infiltration. T1-weighted scouting sequences (Look-Locker) incorporating a range of inversion times are helpful to differentiate extensive LGE from poor myocardial nulling. It may also be helpful to cross-check skeletal muscle signal intensity while choosing the optimal inversion time, particularly in difficult cases; very bright skeletal muscle signal should prompt a reconsideration of the inversion time (Fig. 7).

Gadolinium is an extracellular tracer, and previous studies have confirmed good correlation between LGE and increased extracellular space on histological examination in aortic stenosis (14) and cardiac amyloidosis (8). A base-apex gradient, common in ATTR amyloidosis in this study, correlates with echocardiographic studies using strain analysis, which have reported reduced basal systolic longitudinal and radial strain (“apical sparing”) in cardiac amyloidosis (15). The base-apical gradient

**Figure 2. Examples of LGE Patterns in ATTR and AL Amyloidosis**


(Left) A horizontal long-axis late gadolinium enhancement (LGE) image from a patient with ATTR amyloidosis, highlighting the base-apex gradient. (Right) A horizontal long-axis image from a patient with cardiac AL amyloidosis with global subendocardial LGE. Abbreviations as in Figure 1.



also reflects underlying myocardial wall stress in the left ventricle (16).

It remains unclear why survival in cardiac AL amyloidosis is inferior to cardiac ATTR amyloidosis. LGE has been reported as a marker of poor prognosis in ischemic, dilated, and hypertrophic cardiomyopathies (17–19). Although Syed et al. (10) reported increased B-natriuretic peptide concentration in amyloidosis patients (predominantly AL type) with LGE, there was no correlation between NT-proBNP and LGE when quantified with the QALE score in this study. Patients with cardiac ATTR amyloidosis in this series had a better prognosis despite more extensive LGE. The previously reported subendocardial LGE pattern is characteristic of AL amyloidosis, but it is very often not global as described and incorporates a degree of transmural enhancement, typically in the basal lateral wall. We have therefore refined the description of global subendocardial LGE resulting in the pattern presenting infrequently in this series. It is possible that the precise anatomical pattern of LGE (rather than merely the extent of LGE) in amyloidosis has a major influence on causing cardiac dysfunction, with subendocardial deposition potentially causing more marked restrictive

physiology. Diastolic function is not formally assessed with routine CMR, and correlation of the findings in this study with echocardiography is warranted. Direct toxicity of AL amyloid fibrils on






Figure 5. Reproducibility of QALE Scores

Bland-Altman plot demonstrating good agreement between 2 independent observers reporting QALE scores in patients with AL and ATTR cardiac amyloidosis (**blue line** = mean difference; **grey lines** = 2 SDs from the mean difference; upper limit 6.53; lower limit -9.09). Abbreviations as in Figures 1 and 3.

myocardial cells has been proposed as an alternative explanation (20), but it is also possible that the likely much slower accumulation of ATTR amyloid is better tolerated. No significant difference was demonstrated between nonmutant ($n = 23$) and mutant ATTR ($n = 28$) type for any CMR variable in this series.

The newly devised CMR LGE scoring outlined in this study was an independent predictor of amyloid type on multivariate analysis. The logistic

regression scoring model differentiated ATTR and AL type with high sensitivity and specificity, and we have confirmed an improvement in accuracy by adding the QALE score. Echocardiography has poor specificity (74% to 82%) to detect amyloid from nonamyloid cardiomyopathy (21), even using modern speckle tracking strain analysis techniques (15), and it thus seems inferior to CMR in differentiating between amyloid types (although this has not been formally assessed). ^{99m}Tc -3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy seems to have high specificity to differentiate amyloid types, but it has been studied in much smaller numbers (22). CMR is currently more widely available than ^{99m}Tc -DPD scintigraphy and also provides additional functional and structural information.

CMR LGE scoring seems to differentiate between amyloid types but the technique requires validation in additional prospective studies. Novel T1 mapping techniques have been shown to provide quantitative assessment of diffuse extracellular expansion in other cardiomyopathies (23,24). T1 mapping may become the gold standard for quantifying the extent of interstitial expansion by amyloid deposition (25), but it may not be possible to implement the technique into standard clinical practice for all patients due to limited availability (CMR scanning is often performed locally before specialist center referral).

Given the retrospective nature of the current study, and the lack of evaluation in a prospective cohort, we accept that treatment decisions should not be based on CMR findings alone, and histological diagnosis (including amyloid type differentiation) remains the gold standard. LGE is not specific to cardiac amyloidosis, and false-positive reporting occurs in the clinical setting. Extensive fibrosis, for example secondary to hypertrophic cardiomyopathy or hypertensive heart disease, may result in diffuse LGE and false-positive CMR findings. The absence of transmural LGE or a base-apex gradient in all patients with false-positive CMR reports in this series may help to identify patients requiring further noninvasive investigation (e.g., ^{99m}Tc -DPD scintigraphy) before proceeding to endomyocardial biopsy.

Study limitations. We reported a retrospective analysis of CMR studies. De novo analyses were performed by using the original DICOM data; however, we accept the inherent bias of retrospective, nonrandomized studies. Multiple CMR scanners and protocols were used in this series, and we acknowledge a significant referral bias because we




Figure 6. False-Positive Example

An example of diffuse mid-wall LGE reported as suggestive of cardiac amyloidosis. Cardiac biopsy results demonstrated extensive myocardial fibrosis with negative Congo red staining. This pattern was found in 2 Afro-Caribbean patients with hypertensive heart disease. Abbreviation as in Figure 2.

did not include patients in whom amyloidosis was not considered. Although a single-center, optimized “amyloid protocol” is the ideal, in reality, patients are referred to specialist centers from many different units, and the diagnosis is not always known at the time of the scan. Optimized LGE sequences for utilization in ischemic cardiomyopathy are recognized to provide reliable and reproducible findings across vendors and field strengths. Each study in this series was reported separately by 2 CMR operators, with 1 observer blinded to the final diagnosis, and the QALE score was compared for all studies with fair reproducibility.


Scan quality is often suboptimal in cardiac amyloidosis patients due to poor breath-holding, arrhythmias, and effusions, and a total of 7 scans obtained were uninterpretable and not included in the analyses. Inability to adequately null the myocardium was evident in 25% of cases with AL or ATTR type, but, with persistent effort, sufficient information was derived in the majority. The conclusions on the original reports were generally sound, but paradoxical deductions were reached in a few cases (e.g., no LGE reported despite phase-sensitive inversion recovery sequences demonstrating diffuse transmural enhancement, which was disregarded due to suboptimal nulling).

We used gold standard echocardiographic criteria in AL amyloidosis for comparison of CMR data because endomyocardial biopsy testing is not always appropriate, particularly in patients with noncardiac biopsy proof of amyloidosis type. Conventional noninvasive criteria for cardiac ATTR amyloidosis were not available at the time of publication.

CONCLUSIONS

CMR is often performed to assess patients with suspected amyloidosis or it triggers the differential after an abnormal scan result. The increased availability of CMR will ultimately lead to increased detection of cardiac amyloidosis due to superior tissue characterization, using the LGE technique, compared with echocardiography. This study was a real-world analysis of scans performed in 46 centers without specialist amyloid protocols, and we acknowledge all of the difficulties of the LGE technique. Despite these limitations, the analysis was robust in identifying the amyloid fibril type with high accuracy. CMR LGE scoring has the potential to enhance the management of many patients but cannot replace biopsy as the gold standard.

Cardiac amyloidosis should be considered in any patient with LGE and LV hypertrophy,



particularly in the presence of preserved ejection fraction and pleural effusions. We have attempted to differentiate between the 2 main subtypes of cardiac amyloidosis, a crucial differentiation due to markedly different outcomes. Cardiac ATTR amyloidosis is associated with improved survival despite increased LV mass and more extensive LGE, a finding at odds with other cardiomyopathies. The explanation for this finding needs further investigation.

Correct identification of amyloidosis type is imperative to differentiate patients with cardiac AL amyloidosis, a condition potentially amenable to chemotherapy, from cardiac ATTR amyloidosis patients who may benefit from novel TTR-specific treatments now entering Phase III clinical trial assessment.

Acknowledgments

The authors acknowledge all of the cardiologists and radiologists who were involved in performing the clinical CMR scans that contributed to the data presented in this study. The authors thank Rose Coughlan and Pam Thomson for their hard work arranging the transfer of CMR studies from referring centers, and St. George's University of London media services for help with the QALE figure.

Reprint requests and correspondence: Dr. Jason N. Dungu, St. George's University of London, Cranmer Terrace, London SW17 0RE, United Kingdom. *E-mail:* jdungu@sgul.ac.uk.

REFERENCES

- Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. *N Engl J Med* 1997;337:898–909.
- Dubrey S, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. *QJM* 1998;91:141–57.
- Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. *Br J Haematol* 2008;143:369–73.
- Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. *Heart* 2012;98:1546–54.
- Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. *J Mol Biol* 1978;121:339–56.
- Connors LH, Lim A, Prokoeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. *Amyloid* 2003;10:160–84.
- White SK, Sado DM, Flett AS, Moon J. Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging. *Heart* 2012;98:773–9.
- Maccera AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. *Circulation* 2005;111:186–93.
- Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. *J Am Coll Cardiol* 2008;51:1022–30.
- Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. *J Am Coll Cardiol* 2010;3:155–64.
- Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL). *Am J Hematol* 2005;79:319–28.
- Hundley WG, Bluemke D, Bogaert JG, et al. Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. *J Cardiovasc Magn Reson* 2009;11:5.
- Bland JM, Altman DG. Measuring agreement in method comparison studies. *Stat Methods Med Res* 1999;8:135–60.
- Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. *Circulation* 2010;122:138–44.
- Phelan D, Collier P, Thavendiranathan P, et al. Relative “apical sparing” of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. *Heart* 2012;98:1442–8.
- Balzer P, Furber A, Delépine S, et al. Regional assessment of wall curvature and wall stress in left ventricle with magnetic resonance imaging. *Am J Physiol* 1999;277:H901–10.
- Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. *Circulation* 2006;113:2733–43.
- Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. *J Am Coll Cardiol* 2006;48:1977–85.
- O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2010;56:867–74.
- Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. *Circulation Res* 2004;94:1008–10.
- Falk RH, Ukk M, Plehn JF, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. *Am J Cardiol* 1987;59:418–22.
- Quarta CC, Guidalotti PL, Longhi S, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. *J Am Coll Cardiol* 2012;5:755–8.
- Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. *J Am Coll Cardiol* 2008;52:1574–80.
- Ugander M, Oki AJ, Hsu LY, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. *Eur Heart J* 2012;33:1268–78.
- Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. *J Am Coll Cardiol* 2012;5:897–907.

Key Words: amyloid ■
cardiomyopathy ■ magnetic
resonance imaging.

► APPENDIX

For a supplemental figure and tables, please see the online version of this article.